Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Gibco™ Insulin-Transferrin-Selenium-Sodium Pyruvate (ITS-A) (100X)
A basal medium supplement to reduce the amount of fetal bovine serum (FBS) needed to culture cells
Supplier: Gibco™ 51300044
Description
- Used for adherent cell cultures
- Originally used with RPMI 1640 and Minimum Essential Medium (MEM), ITS-A is now routinely used with other basal media to support a wide variety of cell types in the presence of 2 to 4% FBS
- Insulin promotes glucose and amino acid uptake, lipogenesis, intracellular transport, and the synthesis of proteins and nucleic acids
- Transferrin is an iron carrier and it may also help to reduce toxic levels of oxygen radicals and peroxide
- Selenite is a cofactor for glutathione peroxidase and other proteins, and is used as an antioxidant in media
- Sodium Pyruvate is a precursor to amino acids, fatty acids, and cholesterol; it is an important intermediate in many biosynthetic pathways
- Manufactured at a cGMP compliant facility, located in Grand Island, New York, registered with the FDA as a medical device manufacturer and certified to ISO 13485 standards
Order Info
Shipping Condition: Room Temperature
Specifications
Storage conditions: 2 to 8°C Shipping conditions: Ambient Shelf life: 18 months from date of manufacture |
|
100 X | |
Transferrin | |
Sodium Pyruvate | |
10 mL |
Mammalian Cells | |
Mammalian Cell Culture | |
Sterile-filtered | |
No Phenol Red | |
Room Temperature |
Safety and Handling
ShelfLife : 18 Months
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
For Research Use Only. Not for use in diagnostic procedures.
Spot an opportunity for improvement?Share a Content Correction